** U.S.-listed shares of Scinai Immunotherapeutics 2F5y.F, SCNI.O rise 104% to $5.15
** Stock set for its best day on record, if gains hold
** Co says it received Italian government's clearance to potentially acquire Italian biotech firm Pincell, which is developing novel antibody to treat severe skin conditions
** Approval removes major regulatory hurdle for acquisition but does not finalize deal, SCNI says
** Scinai plans to acquire 100% of Pincell's share capital and voting rights
** Acquisition, initially agreed in March, still requires meeting additional conditions before completion, co says
** Pincell's lead drug, antibody PC111, is being developed to treat rare and severe skin disorders
** Including session's moves, SCNI up 54.3% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。